

# Medical Drug Clinical Criteria

<b>Subject:</b>	Vyepti (eptinezumab)		
<b>Document #:</b>	CC-0160	<b>Publish Date:</b>	10/23/2023
<b>Status:</b>	Revised	<b>Last Review Date:</b>	09/11/2023

## Table of Contents

<a href="#">Overview</a>	<a href="#">Coding</a>	<a href="#">References</a>
<a href="#">Clinical criteria</a>	<a href="#">Document history</a>	

## Overview

This document addresses the use of Vyepti (eptinezumab), a calcitonin gene-related peptide (CGRP) inhibitor agent for migraine prophylaxis. The CGRP system is involved with vascular homeostasis. During a migraine, CGRP levels increase resulting in vasodilation, pro-inflammatory effects and pain signaling. Vyepti is FDA approved for the prophylaxis of migraine headaches.

Please refer to the following clinical criteria for additional information:

- Self-Injected Calcitonin Gene-Related Peptide (CGRP) Agents
- Calcitonin Gene-Related Peptide (CGRP) Step Therapy

Vyepti is an infused agent that requires administration via healthcare professional every 3 months. The dose recommendation per label for Vyepti is 100 mg every 3 months. However, the label indicates that some patients may benefit from a dosage of 300 mg.

## Clinical Criteria

When a drug is being reviewed for coverage under a member's medical benefit plan or is otherwise subject to clinical review (including prior authorization), the following criteria will be used to determine whether the drug meets any applicable medical necessity requirements for the intended/prescribed purpose.

### Vyepti (eptinezumab)

Initial requests for Vyepti (eptinezumab) may be approved when the following criteria are met:

- I. Individual has a diagnosis of one of the following:
  - A. Episodic migraine defined as at least 4 and fewer than 15 migraine days per month and fewer than 15 headache days per month on average during the previous 3-month period; **OR**
  - B. Chronic migraine defined as a headache occurring on 15 or more days per month for more than 3 months, which, on at least 8 days per month, has features of a migraine headache (ICHD-3);

#### **AND**

- II. Individual is using Vyepti for migraine prophylaxis;

#### **AND**

- III. Individual has had a trial of and inadequate response to a 2-month trial at target or usual effective dose or intolerance to two agents for migraine prophylaxis (at least one agent in any two of the following classes) or has a contraindication to all of the following medications (AAN/AHA 2012/2015, Level A and B evidence; ICSI 2013, high quality evidence, AHS 2021):
  - A. The following antidepressants: amitriptyline, venlafaxine, nortriptyline, duloxetine; **OR**
  - B. One of the following beta blockers: Metoprolol, propranolol, timolol (oral), nadolol, atenolol, nebivolol; **OR**
  - C. The following calcium channel blocker: verapamil; **OR**
  - D. One of the following antiepileptic agents: valproate sodium, divalproex sodium, topiramate, gabapentin; **OR**
  - E. Botox (for chronic migraine);

#### **AND**

- IV. If individual is also currently using botulinum toxin for prophylaxis and is going to be using Vyepti and botulinum toxin together (i.e., not switching from one agent to another), the following must apply:
  - A. Individual has had a reduction in the overall number of migraine days or reduction in number of severe migraine days per month with the initial agent; **AND**

- B. Individual continues to experience a significant number of migraine headache days or severe migraine days per month requiring additional therapy for migraine prevention.

Renewal requests for Vyepti (eptinezumab) may be approved when the following criteria are met:

- I. Individual has a reduction in the overall number of migraine days or reduction in number of severe migraine days per month; **AND**
- II. Individual has obtained clinical benefit deemed significant by individual or prescriber including any of the following (AHS 2021):
  - A. 50% reduction in frequency of days with headache or migraine; **OR**
  - B. Significant decrease in attack duration; **OR**
  - C. Significant decrease in attack severity; **OR**
  - D. Improved response to acute treatment; **OR**
  - E. Reduction in migraine-related disability and improvements in functioning in important areas of life; **OR**
  - F. Improvements in health-related quality of life and reduction in psychological stress due to migraine;

**AND**

- III. If individual is using concurrently with botulinum toxin, the following must apply:
  - A. Individual has had further reduction in the overall number of migraine days or reduction in number of severe migraine days per month compared to monotherapy with the initial agent (either botulinum toxin or Vyepti).

Vyepti (eptinezumab) may not be approved for the following:

- I. Individual is using in combination with another prophylactic CGRP agent (Ajovy, Aimovig, Emgality, Qulipta or prophylactic use of Nurtec ODT).

**Approval duration:**

- Initial request: 6 months (two injection cycles)
- Renewal requests: 1 year

**Step Therapy**

**Note:** When a calcitonin gene-related peptide (CGRP) inhibitor is deemed approvable based on the clinical criteria above, the benefit plan may have additional criteria requiring the use of a preferred<sup>1</sup> agent or agents.

**Calcitonin gene-related peptide (CGRP) Inhibitor Step Therapy**

A list of the preferred calcitonin gene-related peptide (CGRP) inhibitors is available [here](#).

Requests for a non-preferred calcitonin gene-related peptide (CGRP) inhibitor may be approved when the following criteria are met:

- I. Individual has had a trial of and inadequate response or intolerance to one preferred CGRP agent;

<sup>1</sup>Preferred, as used herein, refers to agents that were deemed to be clinically comparable to other agents in the same class or disease category but are preferred based upon clinical evidence and cost effectiveness.

**Quantity Limits**

**Vyepti (eptinezumab) Quantity Limit**

Drug	Limit per 3 months
Vyepti (eptinezumab) 100 mg/mL vial	1 vial (100 mg)
Override Criteria	
Individuals who have had an inadequate response to 100 mg dose may be approved for 3 vials (300 mg) every 3 months	

**Coding**

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

**HCPCS**

J3032 Injection, eptinezumab-jjmr, 1 mg (Effective 10/1/2020)

### ICD-10 Diagnosis

G43.001-G43.919 Migraine, unspecified

## Document History

Reviewed: 09/11/2023

Document History:

- 09/11/2023 – Select Review: Clarify quantity limit override. Coding Reviewed: No changes.
- 05/19/2023 – Annual Review: No changes. Coding Reviewed: No changes.
- 03/27/2023 – Step therapy table updates.
- 05/20/2022 – Annual Review: Update exclusion for combination use to include additional prophylactic agents; reformat duplication therapy with botulinum toxin criteria for clarity; update references. Coding Reviewed: No changes.
- 05/21/2021 – Annual Review: Updated criteria to include specific examples of clinical benefit from prophylaxis, updated criteria to include clinical criteria for concurrent use with botulinum toxin for migraine prophylaxis, updated criteria to prevent combination therapy between prophylactic CGRP agents; updated approval duration based on AHS 2019 to 6 months due to administration frequency of every 3 months. Coding Reviewed: No changes.
- 04/26/2021 – Step Therapy table update.
- 03/23/2021 – Step Therapy table update.
- 10/26/2020 – Administrative update to add step therapy.
- 05/15/2020 – Annual Review: Minor wording and formatting update. Coding reviewed: Added HCPCS C9063 (Effective 7/1/2020) Effective 10/1/2020 Added HCPCS J3032, Delete 9/30/2020 HCPCS J3490, J3590, C9063
- 03/02/2020 – Selected review: New criteria document for Vyepti; Added quantity limit for Vyepti per label with override criteria for higher dose. Coding Reviewed: New policy. Added HCPCS J3490, J3490, G43.001-G43.919.

## References

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2023. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2023; Updated periodically.
5. Beithon J, Gallenberg M, Johnson K, Kildahl P, Krenik J, Liebow M, Linbo L, Myers C, Peterson S, Schmidt J, Swanson J. Institute for Clinical Systems Improvement. Diagnosis and Treatment of Headache. Available from: [icsi.org/wp-content/uploads/2019/01/Headache.pdf](https://www.icsi.org/wp-content/uploads/2019/01/Headache.pdf). Updated January 2013.
6. The International Classification of Headache Disorders 3<sup>rd</sup> Edition. Available from: <https://www.ichd-3.org/>. Accessed April 22, 2023.
7. Loder E, Burch R, Rizzoli P. The 2012 AHS/AAN Guidelines for Prevention of Episodic Migraine: A summary and comparison with other recent clinical practice guidelines. *Headache*. 2018; 52:930-945.
8. Rapoport AM. How to choose a preventative medication for migraine. American Headache Society. Available from: [https://americanheadachesociety.org/wp-content/uploads/2018/05/Alan\\_Rapoport\\_-\\_Migraine\\_Prevention\\_Medications.pdf](https://americanheadachesociety.org/wp-content/uploads/2018/05/Alan_Rapoport_-_Migraine_Prevention_Medications.pdf).
9. Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults. Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. *Neurology*. 2012; 78:1337–1345.
10. The American Headache Society Consensus statement: Update on integrating new migraine treatments into clinical practice. *Headache*. 2021; 61:1021-1039.
11. Dodick DW, Lipton RB, Silberstein S, et.al. Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial. *Cephalgia*. 2019; 39(9):1075-1085.
12. Ashina M, Saper J, Cady R et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). *Cephalgia*. 2020; 0(0): 1-14. Doi: 10.1177/0333102420905132.
13. Blumenfeld AM, Frisberg BM, Schim JD, et.al. Real-world evidence for control of chronic migraine patients receiving CGRP monoclonal antibody therapy added to onabotulinumtoxinA: A retrospective chart review. *Pain Ther*. 21 April 2021. <https://doi.org/10.1007/s40122-021-00264-x>.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

**CC-0160 Vyepiti**

**Commercial Medical Benefit**

<b>Effective Date</b>	<b>Preferred Agents</b>	<b>Non-Preferred Agents</b>
02/01/2021	Aimovig Emgality	Vyepiti

**Medicaid Medical Benefit**

<b>Effective Date</b>	<b>Preferred Agents</b>	<b>Non-Preferred Agents</b>
04/01/2021: MD, NJ, NV, NY, SC, WNY 05/01/2021: GA, IN 04/01/2023: DC	Aimovig Emgality	Vyepiti

**Medicare Medical Benefit**

<b>Effective Date</b>	<b>Preferred Agents</b>	<b>Non-Preferred Agents</b>
N/A	N/A	N/A